Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2016 - 2023)

Myriad Genetics (MYGN) has disclosed Non-Current Deferred Tax Liability for 10 consecutive years, with $2.7 million as the latest value for Q3 2023.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 74.29% to $2.7 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.7 million, a 74.29% decrease, with the full-year FY2022 number at $3.5 million, down 90.22% from a year prior.
  • Non-Current Deferred Tax Liability was $2.7 million for Q3 2023 at Myriad Genetics, down from $3.7 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $82.6 million in Q2 2019 to a low of $2.7 million in Q3 2023.
  • A 5-year average of $42.4 million and a median of $40.7 million in 2021 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: soared 118.8% in 2021, then tumbled 90.22% in 2022.
  • Myriad Genetics' Non-Current Deferred Tax Liability stood at $75.5 million in 2019, then fell by 5.56% to $71.3 million in 2020, then tumbled by 49.79% to $35.8 million in 2021, then crashed by 90.22% to $3.5 million in 2022, then fell by 22.86% to $2.7 million in 2023.
  • Per Business Quant, the three most recent readings for MYGN's Non-Current Deferred Tax Liability are $2.7 million (Q3 2023), $3.7 million (Q2 2023), and $4.1 million (Q1 2023).